Adherence and HIV Protection Thresholds for Emtricitabine and Tenofovir Disoproxil Fumarate Preexposure Prophylaxis among Cisgender Women: A Systematic Review
InfectologiaSobre o estudo
- Desenho
- Revisão sistemática
- Nível de evidência
- 1 · Evidência consolidada
- Revista
- Current HIV/AIDS reports
- Publicado em
- 9 ago 2024
- Citações
- 4
O resumo deste estudo é do publisher e não tem licença aberta: por isso mostramos aqui só os dados do estudo, e o texto fica na fonte original, nos links abaixo.
O estudo original
Adherence and HIV Protection Thresholds for Emtricitabine and Tenofovir Disoproxil Fumarate Preexposure Prophylaxis among Cisgender Women: A Systematic Review
Linxuan Wu, Xin Niu, Marisa Kaitlin Brunelli, Kenneth K Mugwanya
Descritores MeSH
- Tenofovir
- HIV Infections
- Drug Monitoring
- Anti-HIV Agents
- Pre-Exposure Prophylaxis
- Emtricitabine
- Organophosphates
- Pregnancy
- Leukocytes, Mononuclear
- Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination
Veja também
Estudos relacionados
- Adherence thresholds for emtricitabine-tenofovir disoproxil fumarate preexposure prophylaxis against HIV acquisition in cisgender women: A randomized directly observed dosing study
- Evaluation of pharmacokinetics of Tenofovir Alafenamide (TAF) and Tenofovir Disoproxil (TDF) in pregnant and postpartum women in South Africa: PrEP-PP PK study
- Twice-Yearly Lenacapavir or Daily F/TAF for HIV Prevention in Cisgender Women
- Exploring potential drug-drug interactions between masculinizing hormone therapy and oral pre-exposure prophylaxis (F/TDF and F/TAF) among transgender men (iMACT study): a randomized, open-label pharmacokinetic study in Thailand